Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Tumor of Brain Clear all
Completed Phase 2 Interventional

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

NCT00600054
View directory record Official record
Conditions
Recurrent Diffuse Pontine Gliomas
Interventions
nimotuzumab (anti EGFR humanized monoclonal antibody)
Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
3 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

NCT02444546
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Metformin in Children With Relapsed or Refractory Solid Tumors

NCT01528046
View directory record Official record
Conditions
Solid Tumors, Primary Brain Tumors
Interventions
Vincristine, Irinotecan, Temozolomide, Metformin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Hartford, Connecticut • Wilmington, Delaware • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 11, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

NCT05768880
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions
SC-CAR4BRAIN
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2043
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

NCT00946335
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
veliparib, temozolomide, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Results available

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

NCT02564198
View directory record Official record
Conditions
Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
Interventions
Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Monrovia, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 11, 2026, 5:48 AM EDT
Active, not recruiting Phase 4 Interventional

Pediatric Long-Term Follow-up and Rollover Study

NCT03975829
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 99 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 11, 2026, 5:48 AM EDT
Completed No phase listed Observational

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT01445288
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 11, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Early Phase 1 Interventional

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

NCT01748149
View directory record Official record
Conditions
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Interventions
Vemurafenib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 11, 2026, 5:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349
View directory record Official record
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

NCT03257631
View directory record Official record
Conditions
Central Nervous System Neoplasms, Medulloblastoma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

NCT01393912
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma
Interventions
Crenolanib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Months to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845
View directory record Official record
Conditions
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Interventions
G207
Biological
Lead sponsor
Gregory K. Friedman, MD
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and Propofol for Pediatric MRI Sedation

NCT03513757
View directory record Official record
Conditions
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions
propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months to 60 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

NCT00002594
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
Sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 11, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional

9-ING-41 in Pediatric Patients With Refractory Malignancies.

NCT04239092
View directory record Official record
Conditions
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions
9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
Up to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 11, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

Methionine PET/CT Studies In Patients With Cancer

NCT00840047
View directory record Official record
Conditions
Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma, High Grade CNS Tumors, Ependymoma, Medulloblastoma, Craniopharyngioma, Low Grade CNS Tumors, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Other
Interventions
Methionine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 11, 2026, 5:48 AM EDT
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients

NCT01512147
View directory record Official record
Conditions
Tethered Spinal Cord, Brain Tumor, Cranio Cervical Compression
Interventions
Isoflurane, Propofol, Dexmedetomidine
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 11, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

NCT00024258
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 11, 2026, 5:48 AM EDT
Completed No phase listed Observational

Components of Social Functioning in Survivors of Pediatric Brain Tumors

NCT03361033
View directory record Official record
Conditions
Brain Tumor, Pediatric, Medulloblastoma, Pediatric
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 11, 2026, 5:48 AM EDT